Algorae Pharmaceuticals Seeks ASX Quotation for 172.7 Million New Shares

Living Cell Technologies ( (AU:1AI) ) has shared an announcement.

Algorae Pharmaceuticals has applied for quotation on the ASX of 172,687,970 ordinary fully paid shares, with an issue date of April 2, 2026. The application, lodged as a new announcement on April 7, 2026, reflects a significant expansion of the company’s quoted share capital, with potential implications for liquidity and the ownership structure of its securities.

The newly quoted securities arise from the exercise or conversion of options or other convertible instruments into ordinary shares. This step aligns Algorae Pharmaceuticals with ASX listing requirements and signals continued use of equity-based instruments in its capital structure, which may affect existing shareholders through dilution while supporting funding flexibility.

The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.

More about Living Cell Technologies

Algorae Pharmaceuticals Limited operates in the pharmaceuticals sector and is listed on the ASX under the code 1AI. The company issues ordinary fully paid shares as part of its capital management and financing activities in the public equity markets.

YTD Price Performance: 14.29%

Average Trading Volume: 1,506,343

Technical Sentiment Signal: Hold

Current Market Cap: A$28.18M

For a thorough assessment of 1AI stock, go to TipRanks’ Stock Analysis page.